Related references
Note: Only part of the references are listed.The accuracy of absorbed dose estimates in tumours determined by Quantitative SPECT: A Monte Carlo study
Michael Ljungberg et al.
ACTA ONCOLOGICA (2011)
Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues
Edgar J. Rolleman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Individualized dosimetry in patients undergoing therapy with 177Lu-DOTA-D-Phe1-Tyr3-octreotate
Mattias Sandstrom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2010)
Fine-Resolution Voxel S Values for Constructing Absorbed Dose Distributions at Variable Voxel Size
Arnaud Dieudonne et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0, Tyr3] octreotate:: Toxicity, efficacy, and survival
Dik J. Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MIRD Pamphlet No. 20: The Effect of Model Assumptions on Kidney Dosimetry and Response-Implications for Radionuclide Therapy
Barry W. Wessels et al.
JOURNAL OF NUCLEAR MEDICINE (2008)
Clinical radionuclide therapy dosimetry: the quest for the Holy Gray
Glenn Flux et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2007)
Method for fast CT/SPECT-based 3D Monte Carlo absorbed dose computations in internal emitter therapy
S. J. Wilderman et al.
IEEE TRANSACTIONS ON NUCLEAR SCIENCE (2007)
RECIST revisited: A review of validation studies on tumour assessment
P. Therasse et al.
EUROPEAN JOURNAL OF CANCER (2006)
Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3] octreotate in patients with endocrine gastroenteropancreatic tumors
DJ Kwekkeboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pre-therapeutic dosimetry and biodistribution of 86Y-DOTA-Phe1-Tyr3-octreotide versus 111In-pentetreotide in patients with advanced neuroendocrine tumours
A Helisch et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2004)
Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours
L Bodei et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2004)
86Y-DOTA0-D-Phe1-Tyr3-octreotide (SMT487) -: a phase 1 clinical study:: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion
F Jamar et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
3D absorbed dose calculations based on SPECT:: Evaluation for 111-In/90-Y therapy using Monte Carlo simulations.
M Ljungberg et al.
CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS (2003)
Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine
EJ Rolleman et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2003)
[177Lu-DOTA0,Tyr3]octreotate:: comparison with [111In-DTPA0]octreotide in patients
DJ Kwekkeboom et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE (2001)
Share Paper
